Search Results 231-240 of 15310 for TNF

  1. CardiolRx In Recurrent Pericarditis Following IL-1 Blocker Cessation - Mayo Clinic

    Canakinumab, TNF inhibitors, IL-6 inhibitors, or janus-activating kinase inhibitors (within 12 weeks) 4. Intravenous immune globulin (IVIG) (within 8 weeks)

  2. https://www.mayoclinic.org/chinese_patient_consumer_faq.xml

  3. Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) ≤ 2 weeks prior to registration. Note: Patients who have received acute, low dose, systemic immunosuppressant ...

  4. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

  5. https://www.mayoclinic.org/spanish_procedure_concepts.xml

  6. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  8. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Mayo Clinic

    Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g. ...

  9. COVID-19 Tests Clinical Trials - Mayo Clinic Research

    Hypothesis: Baseline cytokine (IL-1β, IL-6, IL-4, IL-10, IFN-g and TNF-a) and the immune cellular repertoire (helper/CD4+, cytotoxic/CD8+, T-regulatory ...

  10. A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1. Patients who have received acute, low dose, systemic immunosuppressant ...